Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 5/2008

01-05-2008 | Original Paper

Small Intestinal Bacterial Overgrowth in Patients with Interstitial Cystitis and Gastrointestinal Symptoms

Authors: Leonard B. Weinstock, Carl G. Klutke, Henry C. Lin

Published in: Digestive Diseases and Sciences | Issue 5/2008

Login to get access

Abstract

Purpose Interstitial cystitis (IC) often coexists with irritable bowel syndrome (IBS). IBS may be explained by small-intestinal bacterial overgrowth (SIBO), which increases immune activation and visceral hypersensitivity. This prospective pilot study tested hypotheses that IC patients with gastrointestinal (GI) symptoms have SIBO, that nonabsorbable antibiotic use improves symptoms, and that improvement is sustained by prokinetic therapy. Methods Consecutive IC patients with GI symptoms had lactulose breath testing (LBT). Those with abnormal results received rifaximin 1,200–1,800 mg/day for 10 days then tegaserod 3 mg/nightly. Questionnaires addressed IC and GI global improvement. Results Of 21 patients, 17 (81%) had abnormal LBTs. Of 15 patients treated, GI global improvement was moderate to great in 11 (73%) and sustained in ten (67%). IC global improvement was moderate to great in six (40%) and sustained in seven (47%). Conclusions A majority of IC patients and GI symptoms had an abnormal LBT suggesting SIBO. Rifaximin improved symptoms, which was sustained by tegaserod.
Literature
1.
Nickel JC (2004) Interstitial cystitis: a chronic pelvic pain syndrome. Med Clin North Am 88:467–481
2.
Giamberardino M (2000) Sex-related and hormonal modulation of visceral pain. In: Fillingim R (ed) Sex gender and pain, vol 17. IASP Press, Seattle
3.
Lin HC (2004) Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 292:852–858PubMedCrossRef
4.
Ritchie J (1973) Pain from distension of the pelvic colon by inflating a balloon in the irritable bowel syndrome. Gut 6:105–112
5.
Fitzgerald MP, Koch D, Senka J (2005) Visceral and cutaneous sensory testing in patients with painful bladder syndrome. Neurourol Urodyn 24:627–632PubMedCrossRef
6.
Tornblom H, Lindberg G, Nyberg B et al (2002) Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 123:1972–1979PubMedCrossRef
7.
Barbara G, Stanghellini V, De Giorgio R et al (2004) Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126:693–702PubMedCrossRef
8.
Sun YN, Luo JY, Shang P et al (2005) Effects of N-methyl-d-aspartate receptor in visceral, hypersensitivity in rats with colonic inflammation. Zhong Nan Da Xue Xue Bao Yi Xue Ban 30:504–509PubMed
9.
Erickson DR, Tomaszewski JE, Kunselman AR et al (2005) Do the National Institute of Diabetes and Digestive and Kidney Diseases cystoscopic criteria associate with other clinical and objective features of interstitial cystitis? J Urol 173:93–97PubMedCrossRef
10.
Pimentel M, Chow EJ, Lin HC (2000) Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95:3505–3506
11.
Pimentel M, Chow EJ, Lin HC (2003) Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98:412–419PubMed
12.
Pimentel M, Park S, Kane SV et al (2006) The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 145:557–563PubMed
13.
Sharara AI, Aoun E, Abdul-Baki H et al (2006) A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101:326–333PubMedCrossRef
14.
Lee HR, Low K, Chatterjee S et al (2006) In the treatment of IBS, the clinical response to rifaximin is determined by the normalization of the lactulose breath test. Am J Gastroenterol 110:A1223
15.
Riordan SM, McIver CJ, Thomas DH et al (1997) Luminal bacteria and small-intestinal permeability. Scand J Gastroenterol 32:556–563PubMedCrossRef
16.
Nieuwenhuijs VB, van Duijvenbode-Beumer H, Verheem A et al (1999) The effects of ABT-229 and octreotide on interdigestive small bowel motility, bacterial overgrowth and bacterial translocation in rats. Eur J Clin Invest 29:33–40PubMedCrossRef
17.
Woodcock NP, Robertson J, Morgan DR et al (2001) Bacterial translocation and immunohistochemical measurement of gut immune function. J Clin Pathol 54:619–623PubMedCrossRef
18.
Sant GR, Theoharides TC (1994) The role of the mast cell in interstitial cystitis. Urol Clin North Am 21:41–53PubMed
19.
Weston AP, Biddle WL, Bhatia PS et al (1993) Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci 38:1590–1595PubMedCrossRef
20.
Peters KM, Diokno AC, Steinert BW (1999) Preliminary study on urinary cytokine levels in interstitial cystitis: does intravesical bacille Calmette-Guerin treat interstitial cystitis by altering the immune profile in the bladder? Urology 54(3):450–453PubMedCrossRef
21.
Dunlap SP, Hebden J, Campbell E (2006) Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 101:1288–1294CrossRef
22.
Warren JM, Horne LM, Hebel JR et al (2000) Pilot study of sequential oral antibiotics for the treatment of interstitial cystitis. J Urol 163:1685–1688PubMedCrossRef
23.
Di Stefano M, Vos R, Janssens J et al (2003) Effect of tegaserod, a 5-HT4 receptor partial agonist, on interdigestive and postprandial gastrointestinal motility in healthy volunteers. Gastroenterology 126:A105412
24.
Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC (2002) Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci 47:2639–2643PubMedCrossRef
25.
Weinstock LB, Tordorczuk JT, Fern SE et al (2006) Comprehensive SIBO therapy of IBS patients. Am J Gastroenterol 110:A1123
26.
Weinstock LB, Tordorczuk JT, Fern SE et al (2006) Comprehensive SIBO therapy of functional bowel patients. Am J Gastroenterol 110:A1124
27.
Huang DB, DuPont HL (2005) Rifaximin – a novel antimicrobial for enteric infections. J Infect 50:97–106PubMedCrossRef
28.
Minocha A, Rashid S (1997) Reliability and reproducibility of breath hydrogen and methane in male diabetic subjects. Dig Dis Sci 42:672–676PubMedCrossRef
29.
Eckburg PB, Bik EM, Bernstein CN et al (2005) Diversity of the human intestinal microbial flora. Science 308:1635–1638PubMedCrossRef
30.
Strocchi A, Furne J, Ellis C et al (1994) Methanogens outcompete sulphate reducing bacteria for H2 in the human colon. Gut 35:1098–1101PubMedCrossRef
31.
Levitt MD, Furne J, Springfield J et al (1999) Detoxification of hydrogen sulfide and methanethiol in the cecal mucosa. J Clin Invest 104:1107–1114PubMedCrossRef
32.
Attene-Ramos MS, Wagner ED, Plewa MJ, Gaskins HR (2006) Evidence that hydrogen sulfide is a genotoxic agent. Mol Cancer Res 4:9–14PubMedCrossRef
33.
Patacchini R, Santicioli P, Giuliani S, Maggi CA (2005) Pharmacological investigation of hydrogen sulfide (H2S) contractile activity in rat detrusor muscle. Eur J Pharmacol 509:171–177PubMedCrossRef
34.
Patacchini R, Santicioli P, Giuliani S, Maggi CA (2004) Hydrogen sulfide (H2S) stimulates capsaicin-sensitive primary afferent neurons in the rat urinary bladder. Br J Pharmacol 142:31–34PubMedCrossRef
35.
Boucher W, el-Mansoury M, Pang X, Sant GR, Theoharides TC (1995) Elevated mast cell tryptase in the urine of patients with interstitial cystitis. Br J Urol 76:94–100PubMedCrossRef
36.
Chiang G, Patra P, Letourneau R, Jeudy S, Boucher W, Green M, Sant GR, Theoharides TC (2003) Pentosanpolysulfate (Elmiron) is a potent inhibitor of mast cell histamine secretion. Adv Exp Med Biol 539(Pt B):713–729PubMed
37.
Coelho AM, Fioramonti J, Bueno L (2000) Systemic lipopolysaccharide influences rectal sensitivity in rats: role of mast cells, cytokines and vagus nerve. Am J Physiol Gastrointestinal Liver Physiol 279:G781–G790
38.
Barbara G, Stanghellini V, De Giorgio R et al (2006) Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil 18:6–17PubMedCrossRef
39.
Pezzone MA, Liang R, Fraser MO (2005) A model of neural cross-talk and irritation in the pelvis: implications for the overlap of chronic pelvic pain disorders. Gastroenterology 128:1953–1954PubMedCrossRef
40.
Theoharides TC (1996) The mast cell: a neuroimmunoendocrine master player. Int J Tissue React 18:1–21PubMed
Metadata
Title
Small Intestinal Bacterial Overgrowth in Patients with Interstitial Cystitis and Gastrointestinal Symptoms
Authors
Leonard B. Weinstock
Carl G. Klutke
Henry C. Lin
Publication date
01-05-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 5/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-0022-z

Other articles of this Issue 5/2008

Digestive Diseases and Sciences 5/2008 Go to the issue

Original Paper

Comparative Effects of Several Therapatic Agents on Hepatic Damage Induced by Acute Experimental Pancreatitis

Original Paper

Effect of Cholecystectomy on Gastric and Esophageal Bile Reflux in Patients with Upper Gastrointestinal Symptoms

Letter

Management of De novo Hepatocellular Carcinoma Developing in a Transplanted Liver

Original Paper

Endoscopic Visualization of Angiotensin-converting Enzyme Inhibitor-induced Small Bowel Angioedema as a Cause of Relapsing Abdominal Pain using Double-balloon Enteroscopy

Original Paper

Oral Insulin Up-regulates Toll-like Receptor 4 Expression and Enhances Intestinal Recovery Following Lipopolysaccharide-induced Gut Injury in a Rat

Original Paper

Comparative Studies on Expression of α-Smooth Muscle Actin in Hepatic Stellate Cells in Chronic Hepatitis B and C
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits